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a  b  s  t  r  a  c  t
We  conducted  a  cross-sectional  seroprevalence  study  to  determine  hepatitis  B vaccination  coverage  and
hepatitis  B  virus  (HBV)  immunity  in  a  population  of  young  adult  males.  Speciﬁcally,  the  population  is
comprised  of  Air  Force  conscripts  from  the  metropolitan  region  of  Florianópolis,  Santa  Catarina,  South
Brazil,  who  were  born  prior  to  the  full  implementation  of  the  HBV  vaccination  program.  Of the  371 youngvailable online 29 June 2011
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males  surveyed,  90%  received  at  least  1  dose  of  the  vaccine  and  84%  completed  the  3-dose  schedule.
Overall,  57%  had  positive  anti-HBs  titers.  We  must  continue  to vaccinate  individuals  up  to  20  years  of  age
in  order  to  guarantee  a signiﬁcant  reduction  in  cases  of  hepatitis  B virus.
© 2011 Elsevier Ltd. Open access under the Elsevier OA license.razil
. Introduction
Hepatitis B virus (HBV) infection is still a major public health
roblem in Brazil. It is estimated that at least 15% of the population
as been exposed to HBV [1].
Wide territory and cultural and economic differences inﬂuence
he unequal distribution of hepatitis B throughout the country.
ertain areas have a higher HBV prevalence, such as the western
mazon and even some parts of southern Brazil.
Hepatitis B vaccination began in 1989 in some regions of Brazil
hrough immunization campaigns. In 1998, the vaccine became
vailable in more regions to children younger than 1 year of age
nd to high-risk populations. Afterwards, vaccination coverage was
xtended to health students, members of the military and ado-
escents up to 15 years of age. In Santa Catarina, the vaccine was
ecommended for children younger than 4 in 1993. Then, in 1996,
t was recommended for children up to 15 years. It was only in
001 that the National Immunization Program was extended to all
eenagers up to 19 years of age [2].
Recent studies have demonstrated high hepatitis B vaccination
overage among Brazilian children and adolescents, with rates as
igh as 98% in South Brazil [3–6]. However, current adult vaccina-
ion coverage data consists only of estimates based on the number
f doses administered among children less than 12 months of age
nd the estimated cohort.
∗ Corresponding author. Tel.: +55 48 3721 9712; fax: +55 48 3721 9542.
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Open access under the Elsevier OA license.The achievement of high vaccination coverage in children, ado-
lescents and adults could result in substantial changes in the
hepatitis B infection panorama for the near future. Knowing the
actual vaccination coverage in adults is important for the evaluation
and improvement of current prevention strategies. This study aims
to determine the HBV vaccination coverage and HBV immunity in a
population of young adult Air Force conscripts in the metropolitan
region of Florianópolis (MRF), Santa Catarina, South Brazil.
2.  Patients and methods
This  cross-sectional seroprevalence study was undertaken to
determine vaccination coverage and HBV immunity in young adult
males in the MRF, Santa Catarina. The studied population consisted
of all conscripts of the Brazilian Air Force at the Air Base of Flori-
anópolis during a 1-year period beginning in June 2009. Military
service is mandatory in Brazil, and every male must enroll for ser-
vice at the selection commission in the year he turns 18, regardless
of level of education or socioeconomic status. Each commission is
responsible for the conscripts residing in a speciﬁc region according
to the number of inhabitants of the location.
All conscripts were invited to participate in the study upon their
arrival at the Air Force Base. The invitation was  extended before any
evaluation or test to minimize selection bias.
To successfully estimate vaccination coverage and HBV immu-
nity in this population a minimum sample size of 289 volunteers
was calculated to be sufﬁcient at a 95% conﬁdence interval (CI) and
0.05 alpha error (using an expected probability of HBV vaccination
of approximately 75%) [7,8].
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Table 1
Socio-demographic characteristics and risk factors of unvaccinated young adult males in the Air Force in South Brazil.
Variable Unvaccinated p Variable Unvaccinated p
n % n %
Age (years old) Previous hepatitis
18 12 7.5 0.035* Yes 1 25.0 †
19 7 18.9 No 18 9.4
Ethnicity Hepatitis in the family
White 12  8.7 † Yes 1 4.2 †
Brown/Black 7 12.1 No 18 10.5
Marital  status Blood transfusion
In a relationship 4 12.1 † Yes 1 25.0 †
No relationship 15 9.2 No 18 9.4
Education Piercings or tattoos
<High school 11 16.9  0.016* Yes 6 11.3 †
≥High school 8 6.1 No 13 9.1
Parents  education IDU
≤High  school 15 8.9 † Yes 0 0.0 †
>High school 4 14.8 No 19 9.7
Residency  Unsafe sex
Florianópolis 15 11.5 † Yes 8 10.1 †
MRF  4 6.2 No 11 9.4
Occupation MSM
Yes  9 9.1 † Yes 1 100.0 †
No 10 10.3 No 18 9.2
HMI  STD
1–4  12 9.4 † Yes 0 0.0 †
5 or more 7 10.1 No 19 9.7
n, number of unvaccinated subjects; MRF, metropolitan region of Florianópolis; HMI, household monthly income (minimum wages); IDU, intravenous drug use; MSM,  men
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* Signiﬁcant at p < 0.05 in chi-squared test.
† p > 0.2 in chi-squared test.
Approval for the study was obtained from the Ethics Committee
f the Federal University of Santa Catarina (protocol 136/2009), and
ritten informed consent was obtained from all study participants.
A self-administered standard questionnaire, adapted from one
reviously established and tested [9], was provided to each sub-
ect. The questionnaire asked for socio-demographic characteristics
ncluding age, ethnicity, marital status, highest level of education
chieved by the subject and his parents, residency, occupation and
ousehold monthly income. In addition, the questionnaire asked
bout HBV-related risk factors such as a personal or family history
f hepatitis, blood transfusions, tattoos or piercings, intravenous
rug use, unsafe sex, having sex with another man, and history of
exually transmitted diseases.
Vaccination  cards (VCs) were checked in order to assess cover-
ge characteristics including vaccination status, number of doses
eceived, and age at the time of vaccination.
Blood samples were obtained from all enrolled subjects and
tored at −20 ◦C during transportation to the Laboratory of Clin-
cal Analysis at the Federal University of Santa Catarina Hospital.
BsAg, anti-HBc, anti-HBs and anti-HCV serologies were obtained,
nd each test was performed using automated microparticles
nzymatic immunoassay (Abbott®, AxSYM System, Wiesbaden,
ermany). HBsAg, anti-HBc and anti-HCV results were categorized
s either “positive” or “negative” according to the provided cut-offs.
nti-HBs titers were categorized as “undetectable” if anti-HBs was
ess than the cut-off value, “detectable” if anti-HBs was  less than
0 mIU/mL, and “reactive” if anti-HBs was greater than or equal to
0 mIU/mL, according to the manufacturer’s instructions.
Positive  cases were referred to the nearest health care center for
onﬁrmatory tests and to receive further counseling and monitor-
ng. None of the participants tested positive for HBsAg or anti-HCV.
our subjects were anti-HBc positive and anti-HBs reactive, and
wo subjects were only anti-HBc positive.
Bivariate analysis included Pearson’s chi-square test for the
omparison of categorical values using a signiﬁcance level of
 < 0.050. Non-conditional logistic regression was  used in uni-variate  and multivariate analysis to identify associations between
dependent and independent variables. This model included vari-
ables signiﬁcant at p < 0.200 in Pearson’s chi-square test. All
reported values were two-tailed. The dependent variables included
“non-vaccination”, “non-reactive anti-HBs (<10 mIU/mL)”, “vacci-
nated by the age of 6–18 years”, and “receiving only 1 or 2 doses
of the HBV vaccine (incomplete vaccination schedule)”. The inde-
pendent variables are listed in Tables 1–4. Results are presented as
odds ratios and include the respective 95% CIs.
All data were entered into and analyzed using SPSS version 11.0
(SPSS Inc., Chicago, IL, USA).
3.  Results
A  total of 410 young males were invited to enter the study,
and 371 agreed to participate (91% acceptance). The remaining 39
refused to participate. Among those that entered the study, 53%
(196) had VCs.
Vaccination coverage was 90% among subjects with VCs. When
subjects without VCs were considered unvaccinated, the vaccina-
tion rate of the total sample dropped to 50%.
In all, 84% of subjects with VCs completed the 3-dose schedule.
Among this group, vaccination occurred during the ﬁrst 5 years of
life in 57% of subjects.
Table  1 presents socio-demographic characteristics as well as
possible risk factors for HBV infection among unvaccinated sub-
jects. These unvaccinated adults were older and less educated than
those who were vaccinated (Table 2).
Of all the adults studied, 41% had reactive anti-HBs titers, 16%
had detectable antibodies, and 43% had undetectable anti-HBs.
Non-reactive anti-HBs titers (<10 mIU/mL) were present in 46% of
vaccinated subjects and in all of the unvaccinated participants. A
non-reactive anti-HBs titer was  signiﬁcantly associated with non-
vaccination (p < 0.0001; OR 22.28; 95% CI 2.92–170.12), vaccine
receipt between birth and 5 years of age, and receiving only 1 or 2
doses of the HBV vaccine (Table 3).
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Table  2
Univariate and multivariate logistic regression analysis of the association between non-vaccination and signiﬁcant variables (p < 0.2 in chi-square test).
Variable Unvaccinated (% (n/N)) p OR (95% CI)
Univariate Multivariate
Age (years old)
18  7.5 (12/159) 0.035* 1 1
19 18.9 (7/37) 2.86 (1.04–7.86)* 2.77 (0.99–7.76)
Education
<High school 16.9 (11/65) 0.016* 3.13 (1.19–8.22)* 3.06 (1.15–8.12)*
≥High school 6.1 (8/131) 1 1
n/N, ratio between unvaccinated subjects and total number of individuals in the row; OR, odds ratio; CI, conﬁdence interval.
* Signiﬁcant at p < 0.05.
Table 3
Univariate and multivariate logistic regression analysis of the association between non-reactive anti-HBs (<10 mIU/mL) and signiﬁcant vaccine coverage characteristics
(p < 0.2 in chi-square test).
Variable Non-reactive anti-HBs < 10 mIU/mL (% (n/N)) p  OR (95% CI)
Univariate Multivariate
Age at vaccination
0–5  years old 57.4 (58/101) <0.001* 3.11 (1.66–5.83)* 4.91 (2.35–10.23)*
6–18 years old 30.3 (23/76) 1 1
Vaccine  doses
1–2  doses 64.3 (18/28) 0.032* 2.46 (1.06–5.68)* 5.23 (1.97–13.88)*
n uals in
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r3 doses 42.3  (63/149) 
/N, ratio between subjects with non-reactive anti-HBs and total number of individ
* Signiﬁcant at p < 0.05.
Older adults were more likely to have been vaccinated between
he ages of 6 and 18 years and were more likely to have
nsafe sexual risk factor (Table 4A). Receiving only 1 or 2
oses of the HBV vaccine was associated with having piercings
r tattoos (Table 4B). Those men  who received the HBV vac-
ine between the ages of 6 and 18 were more likely to have
able 4
nivariate and multivariate logistic regression analysis of the association between vaccin
igniﬁcant variables (p < 0.2 in chi-square test).
Vaccination by the age of 6–18 years (% (n/N)) 
(A)
Age (years old)
18  37.4 (55/147) 
19 70.0 (21/30) 
Parents education
≤High  school 44.8 (69/154) 
>High school 30.4 (7/23) 
Unsafe sex
Yes  53.5 (38/71) 
No 35.8 (38/106) 
Receiving 1–2 doses of the HBV vaccine (% (n/N)) 
(B)
Age (years old)
18  13.6 (20/147) 
19 26.7 (8/30) 
Piercings or tattoos
Yes  25.5 (12/47) 
No 12.3 (16/130) 
Unsafe sex
Yes 21.1  (15/71)
No 12.3 (13/106) 
/N, ratio between subjects (A) vaccinated by the age from 6 to 18 years (B) who  received
atio; CI, conﬁdence interval.
* Signiﬁcant at p < 0.05.1 1
 the row; OR, odds ratio; CI, conﬁdence interval.
an  incomplete vaccination schedule (p < 0.001; OR 5.13; 95% CI
2.05–12.84).Young men  without a VC were more likely to be less edu-
cated, to be employed, to have less educated parents, and to have
a lower household income (data not shown). In addition, adults
ation by the age of 6–18 years (A), receiving 1–2 doses of the HBV  vaccine (B) and
p OR (95% CI)
Univariate Multivariate
0.001* 1 1
3.90 (1.67–9.13)* 3.81 (1.60–9.06)*
0.194 1.86 (0.72–4.77) 2.04 (0.76–5.50)
1 1
0.020* 2.06 (1.12–3.80)* 2.00 (1.06–3.78)*
1 1
p OR (95% CI)
Univariate Multivariate
0.074 1 1
2.31 (0.91–5.90) 2.19 (0.84–5.70)
0.033* 2.44 (1.06–5.65)* 2.20 (0.92–5.23)
1 1
0.113 1.92 (0.85–4.32) 1.57 (0.68–3.66)
1 1
 1–2 doses of the HBV vaccine and total number of individuals in the row; OR,  odds
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ithout VCs were more likely to have undetectable anti-HBs titers
p < 0.0001; OR 2.51; 95% CI 1.64–3.82).
Overall,  70% of the studied adults had been vaccinated and/or
ad positive anti-HBs titers.
.  Discussion
Since the hepatitis B vaccine was included in the Brazilian
ational Immunization Program, there has been a substantial
ncrease in vaccination coverage, especially among children and
dolescents [3]. However, cases of hepatitis B have not appeared to
ecrease accordingly, probably due to long incubation and latency
eriods, the misdiagnosis of acute cases, and underreporting of dis-
ase [10]. Mandatory screening has reduced the transmission of
BV through blood transfusions, but sexual transmission remains
 concern among unvaccinated adolescents and adults. This raises
uestions regarding the need to promote vaccination through edu-
ational campaigns, whether the vaccination strategy has been
dequate, and whether vaccination coverage is high enough to
ecrease the occurrence of disease [3].
This vaccination coverage analysis showed a lower rate of vac-
ination than the current estimates, which suggest that 75% of the
opulation younger than 20 years old in Brazil has been vaccinated
10]. Considering the vaccination coverage of subjects in this study
nd the anti-HBs detectable titers, the actual vaccination coverage
n this population may  vary between 57 and 70%. Nevertheless, this
overage is quite low considering that the current hepatitis B vacci-
ation strategy should guarantee the vaccination of all individuals
p to age 20.
Approximately 2/3 of all individuals with proven vaccination
istory received the last dose of the vaccine during the ﬁrst ﬁve
ears of life. Higher dropout rates among subjects vaccinated at
lder ages reinforce the importance of vaccinating children after
irth, the best way of guaranteeing completion of the 3-dose
chedule. Additionally, other vaccines have high coverage, so there
hould be an improvement in coverage if the hepatitis B vaccine is
dministered at the same visit as other routine immunizations.
The  association between low levels of education and non-
accination highlights the importance of reaching lower income
amilies with vaccination awareness campaigns. That is, education
nd socioeconomic status are often linked.
Likewise, a central database should connect each individual to
 vaccination card. This card should be required upon admission to
chool.
Positive anti-HBs serology implies HBV immunity, which may
e acquired through HBV infection or vaccination. Primary vacci-
ation with a 3-dose series results in seroprotection (deﬁned as
he development of anti-HBs levels ≥10 mIU/mL) in at least 95%
f vaccinated individuals. However, following completion of the
rimary series, anti-HBs titers decline and may  fall below this
hreshold, sometimes to undetectable levels. Recent studies argue
hat immunologic memory persists and would be capable of pre-
enting chronic or symptomatic infections for up to 22 years after
accination [11–15]. The rates of HBV immunity in this study may
e between 57 and 70% as the result of the intersection between
ubjects who were vaccinated and those with detectable anti-HBs.
he assumption that the rate of anti-HBs decreases through the
ears is reinforced by the observation that, in this study, adults
eceiving the HBV vaccine at younger ages (0–5 years) were more
ikely to have non-reactive anti-HBs titers.
The importance of completing the 3-dose series of the HBV vac-
ine is further highlighted by the association between receiving
nly 1–2 doses of the HBV vaccine and having a non-reactive anti-
Bs titer (<10 mIU/mL). However, it is unclear in this case whether
he non-reactive anti-HBs are associated with a lack of seroprotec-9 (2011) 9284– 9288 9287
tion  following incomplete vaccination or are expected as antibodies
decrease.
The observation that subjects without VCs were more likely
to have undetectable anti-HBs titers may  be a result of non-
vaccination. However, this might also reﬂect the younger age at
vaccination for this group and a subsequent decrease in anti-HBs,
a possibility that should not be ruled out.
Associations between unsafe sex, piercings or tattoos and vac-
cine coverage characteristics (such as vaccination by the age of 6–18
years and receiving 1–2 doses of the HBV vaccine) also demonstrate
the importance of educational campaigns as fundamental tools for
the horizontal transmission of hepatitis B. Unsafe sex and obtain-
ing piercings or tattoos without precautionary steps may  represent
potential sources of percutaneous exposure [16,17]. The results of
this study are concerning, as these risk factors were more com-
mon in individuals who  received only one or two  doses of the
HBV vaccine and/or remained unvaccinated at the age of 6–18
years.
This study demonstrated, for the ﬁrst time, the rates of HBV
immunity and vaccination coverage in young adults in the MRF
using documented data and serological analysis. This study shows
that there is still an urgent need to improve hepatitis B vac-
cination in this region. The substantial rate of unvaccinated
young adults here suggests that vaccine coverage among adults
older than 19 may  be even more concerning. Therefore, we
must continue our efforts to vaccinate individuals younger than
20. In addition, prevention and awareness campaigns must be
improved. These campaigns should promote safe sex and reach
all people. Furthermore, the creation of vaccination campaigns
targeted at adults should be evaluated, in order to decrease the
rate of HBV infections. With a decrease in rates of HBV, pub-
lic health resources could potentially be redirected from treating
HBV to treating other diseases that cannot be so easily pre-
vented.
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